These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25480344)

  • 1. Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease--a post-hoc analysis of the PARAT trial.
    Melzer N; Bramlage P; Michaelis HC
    BMC Res Notes; 2014 Dec; 7():880. PubMed ID: 25480344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty.
    Grassman ED; Leya F; Fareed J; Lewis BE; Bacher P; Loeb HS; Moran JF
    J Invasive Cardiol; 2001 Nov; 13(11):723-8. PubMed ID: 11689712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 3,000 IU aXa of the low molecular weight heparin certoparin with 5,000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German Thrombosis Study Group.
    Adolf J; Fritsche HM; Haas S; Hennig FF; Horbach T; Kastl S; Koppenhagen K; Michaelis HC; Rhamanzadeh R; Summa W; Wagner W; Weber U; Wolf H
    Int Angiol; 1999 Jun; 18(2):122-6. PubMed ID: 10424367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin.
    Hottelart C; Achard JM; Moriniere P; Zoghbi F; Dieval J; Fournier A
    Artif Organs; 1998 Jul; 22(7):614-7. PubMed ID: 9684701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study.
    Riess H; Haas S; Tebbe U; Gerlach HE; Abletshauser C; Sieder C; Rossol S; Pfeiffer B; Schellong SM
    J Thromb Haemost; 2010 Jun; 8(6):1209-15. PubMed ID: 20218984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency.
    Bauersachs R; Schellong SM; Haas S; Tebbe U; Gerlach HE; Abletshauser C; Sieder C; Melzer N; Bramlage P; Riess H
    Thromb Haemost; 2011 Jun; 105(6):981-8. PubMed ID: 21505722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study.
    Schellong SM; Gerlach HE; Tebbe U; Haas S; Melzer N; Abletshauser C; Sieder C; Bramlage P; Riess H; Bauersachs R
    Thromb Res; 2011 Nov; 128(5):417-21. PubMed ID: 21658750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators.
    Diener HC; Ringelstein EB; von Kummer R; Langohr HD; Bewermeyer H; Landgraf H; Hennerici M; Welzel D; Gräve M; Brom J; Weidinger G
    Stroke; 2001 Jan; 32(1):22-9. PubMed ID: 11136909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial.
    von Tempelhoff GF; Harenberg J; Niemann F; Hommel G; Kirkpatrick CJ; Heilmann L
    Int J Oncol; 2000 Apr; 16(4):815-24. PubMed ID: 10717252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
    Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial.
    Diener HC; Ringelstein EB; von Kummer R; Landgraf H; Koppenhagen K; Harenberg J; Rektor I; Csányi A; Schneider D; Klingelhöfer J; Brom J; Weidinger G;
    Stroke; 2006 Jan; 37(1):139-44. PubMed ID: 16306456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin.
    Haas S; Wolf H; Kakkar AK; Fareed J; Encke A
    Thromb Haemost; 2005 Oct; 94(4):814-9. PubMed ID: 16270636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients.
    Kolb G; Bodamer I; Galster H; Seidlmayer C; Grambach K; Koudela K; Eisele RR; Becker C; Paal V; Spannagel U; Brom J; Weidinger G;
    Thromb Haemost; 2003 Dec; 90(6):1100-5. PubMed ID: 14652643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin.
    Gheno G; Cinetto L; Savarino C; Vellar S; Carraro M; Randon M
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):373-7. PubMed ID: 12851802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
    Jochberger S; Mayr V; Luckner G; Fries DR; Mayr AJ; Friesenecker BE; Lorenz I; Hasibeder WR; Ulmer H; Schobersberger W; Dünser MW
    Crit Care; 2005 Oct; 9(5):R541-8. PubMed ID: 16277716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.